Chemical characterization vs biocompatibility

What Is the Difference Between Chemical Characterization and Biocompatibility Testing?

Chemical characterization vs biocompatibility represents one of the most important distinctions in medical device development: chemical characterization identifies what chemical substances a material contains or releases, while biocompatibility testing determines whether those substances cause harm to living tissue. Together, these two disciplines form the backbone of Materials Metric’s device safety evaluation framework. Understanding how they differ — and how they work together — helps engineers, regulatory teams, and quality managers make smarter, faster compliance decisions.

Furthermore,

Many professionals treat these two processes as interchangeable. However, they serve fundamentally different purposes within the ISO 10993 biological evaluation framework. Moreover, chemical characterization answers the question “What is in this material?” Biocompatibility testing then answers “Is that substance safe for patients?” Consequently, chemical characterization typically comes first, feeding its data directly into the biocompatibility risk assessment process.

In addition,

For medical device manufacturers navigating FDA submissions or CE marking, understanding where chemical characterization ends and biocompatibility begins can save months of rework. Moreover, regulators increasingly expect manufacturers to use chemical characterization data to justify whether biological tests are even necessary. This approach, called risk-based biological evaluation, reduces animal testing and accelerates timelines — but only when teams understand each method’s role and limitations.

Key Takeaways

Chemical characterization identifies chemical substances in or released by a material; biocompatibility testing evaluates whether those substances harm living systems.

ISO 10993-18 governs chemical characterization; ISO 10993-1 governs the overall biological evaluation framework.

Chemical characterization data can reduce or eliminate the need for certain in vitro or in vivo biocompatibility tests.

Both disciplines are complementary — not competing — and together they form a complete biological risk assessment.

Regulators expect manufacturers to document the relationship between chemical findings and biological safety decisions.

Partnering with an experienced laboratory accelerates submissions and reduces costly deficiency responses.

Chemical characterization vs biocompatibility: Chemical characterization is the analytical process of identifying and quantifying chemical substances present in or released from a material or device, while biocompatibility assessment evaluates whether those identified substances or the material as a whole poses an unacceptable biological risk to patients or users — together, these two processes constitute a complete ISO 10993-compliant biological safety evaluation.

However,

Key fact: According to FDA feedback trends, incomplete or missing chemical characterization data is among the leading causes of biocompatibility-related deficiency letters for medical device 510(k) and PMA submissions. Learn more in our article on FDA biocompatibility deficiencies.

What Is Chemical Characterization for Medical Devices?

Therefore,

Chemical characterization is the systematic process of identifying, quantifying, and evaluating chemical substances associated with a medical device or its constituent materials. Consequently, regulators define it formally under ISO 10993-18 Chemical Characterization, which outlines how to plan, conduct, and document chemical analysis. Furthermore, the FDA’s 2023 guidance aligns closely with this standard, making ISO 10993-18 the international benchmark for device manufacturers worldwide.

As a result,

In practice, chemical characterization covers two primary categories: extractables and leachables. Specifically, extractables are chemical compounds released from a material under exaggerated laboratory conditions. Leachables, by contrast, are substances that migrate into a patient-contacting environment under actual use conditions. Both categories require thorough analytical investigation before a device reaches market.

Why Extractables and Leachables Matter

Notably,

Extractables and leachables studies provide the chemical data that regulators and toxicologists need to assess patient risk. Importantly, without this data, a biological evaluation remains incomplete and vulnerable to challenge. Specifically, FDA reviewers expect manufacturers to document what chemicals could potentially reach a patient and at what exposure levels.

Meanwhile,

Analytical techniques commonly used in extractables and leachables studies include GC-MS Analysis, HPLC Analysis, and NMR Spectroscopy. By contrast, each method targets different chemical classes — volatile organics, semi-volatiles, involatile compounds, and inorganic elements. Therefore, a comprehensive extractables study typically employs multiple orthogonal analytical methods rather than relying on any single technique.

Elemental impurities also form a critical part of chemical characterization. For drug-device combination products, USP General Chapter <232> Elemental Impurities sets permitted daily exposure (PDE) limits for toxic metals. Materials Metric’s Chemical & Elemental Characterization services address these requirements with high-sensitivity elemental analysis techniques.

Key Analytical Methods in Chemical Characterization

Selecting the right analytical toolkit is essential for generating regulatory-quality chemical characterization data. Different material types and device contact durations call for different analytical strategies. For instance, polymeric materials often require FTIR Analysis and Raman Spectroscopy to identify polymer composition, additives, and degradation products.

Surface characterization techniques add another layer of information. XPS Analysis reveals elemental composition and chemical bonding states at a material’s outermost surface — a particularly valuable tool for implantable devices. Additionally, XRF Analysis provides rapid, non-destructive bulk elemental screening across a wide range of elements.

Morphological characterization also plays a supporting role, particularly for particulate-releasing devices. SEM Analysis and TEM Analysis help teams visualize particle size, shape, and surface features. Consequently, these techniques support both chemical characterization and downstream toxicological risk assessments for particulate hazards.

The table below summarizes common chemical characterization techniques and their primary applications in device testing:

Analytical Technique	Primary Target	Typical Application
GC-MS	Volatile & semi-volatile organics	Extractables profiling in polymers, adhesives
HPLC	Non-volatile polar compounds	Leachables in aqueous extracts, coatings
FTIR	Polymer identity & functional groups	Material identification, degradation products
XPS	Surface elemental & bonding chemistry	Implant surface analysis, coatings
ICP-MS / XRF	Elemental impurities & metals	Toxic metal screening, USP <232> compliance
NMR	Molecular structure confirmation	Unknown compound identification, purity

What Is Biocompatibility Testing for Medical Devices?

Biocompatibility testing evaluates whether a medical device or its constituent materials cause harmful biological responses when in contact with the human body. ISO 10993-1 defines the overall framework, categorizing tests by device contact type (surface, externally communicating, or implant) and duration (limited, prolonged, or permanent). Importantly, not every device requires every biological test — the standard encourages a risk-based approach informed by chemical characterization data.

Biological endpoints evaluated in biocompatibility programs include cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, carcinogenicity, and reproductive toxicity, among others. Each endpoint addresses a specific biological hazard pathway. Furthermore, the selection of relevant endpoints depends on the device’s intended use, body contact, and duration of exposure.

In Vitro vs. In Vivo Biocompatibility Tests

Biocompatibility tests fall into two broad categories: in vitro (cell-based, laboratory) and in vivo (animal-based) studies. In vitro cytotoxicity testing — often the first test performed — uses cell cultures to screen for cell-killing substances. These studies align with ISO 10993-5 and offer a rapid, cost-effective first-pass biological screen.

In vivo tests, by contrast, involve animal models and provide information on systemic, implantation, or sensitization responses. However, regulators now strongly encourage manufacturers to minimize animal use by leveraging chemical characterization and in vitro data first. Consequently, a well-executed chemical characterization program can reduce or even eliminate certain in vivo testing requirements. Our article on risk-based biocompatibility testing explores this strategy in detail.

How Biological Evaluation Plans Guide Testing Decisions

A Biological Evaluation Plan (BEP) is the strategic document that maps out which biocompatibility tests a device requires — and justifies why certain tests can be waived. Regulators expect this document before testing begins, not after. Therefore, preparing a thorough BEP early in development is a critical success factor for any device program.

The BEP draws heavily on chemical characterization data. For instance, if extractables data shows that all chemical substances fall below established toxicological thresholds, a manufacturer can document a scientifically justified rationale to waive systemic toxicity testing. Moreover, material equivalency arguments — comparing a new device material to one with an established biocompatibility record — can further streamline the evaluation. See our related post on device material equivalency for more on this strategy.

Materials Metric’s Biocompatibility & Toxicity Testing team can help manufacturers develop defensible BEPs that reflect current FDA and ISO 10993 expectations.

Quick note: The FDA increasingly scrutinizes biological evaluation plans that rely solely on published literature or material supplier data sheets, without supporting chemical characterization data generated under controlled laboratory conditions. Generating your own extractables data — specific to your device’s geometry, materials, and processing — strengthens your submission significantly.

Chemical Characterization vs Biocompatibility: Key Differences Explained

Understanding the difference between chemical characterization and biocompatibility testing clarifies how each discipline contributes to device safety. Both processes aim to protect patients, but they approach that goal from different scientific angles. The following comparison highlights the most important distinctions teams need to understand.

Scope, Purpose, and Regulatory Basis

Chemical characterization focuses on identifying and quantifying chemical entities. Its regulatory basis is ISO 10993-18 Chemical Characterization, supplemented by ISO 10993-17 for toxicological risk assessment. Biocompatibility testing, by contrast, assesses biological responses and operates under ISO 10993-1 as the overarching framework, with specific endpoints addressed by ISO 10993-5 through ISO 10993-23 and beyond.

Furthermore, chemical characterization is fundamentally analytical — it generates data about substances. Biocompatibility assessment is fundamentally interpretive and biological — it evaluates whether those substances (or the device as a whole) cause harm. Therefore, these two disciplines require different scientific expertise, equipment, and regulatory documentation strategies.

Timing Within the Development Lifecycle

Chemical characterization typically occurs earlier in the device development process. Teams conduct it during material selection, process development, and pre-submission stages. Specifically, early chemical data allows engineers to reformulate materials, switch suppliers, or adjust processing conditions before biological testing begins.

Biocompatibility testing generally follows chemical characterization, though some in vitro screens may run in parallel. By the time a full biological evaluation plan is executed, chemical characterization data should already be available to inform testing decisions. This sequential logic is central to the risk-based framework outlined in ISO 10993-1 and strongly reinforced in FDA guidance. Our detailed article on FDA chemical characterization review explains what reviewers specifically look for in submission packages.

Feature	Chemical Characterization	Biocompatibility Testing
Primary question	What chemicals are present?	Do those chemicals cause biological harm?
Governing standard	ISO 10993-18	ISO 10993-1 (and associated parts)
Methods used	GC-MS, HPLC, FTIR, XPS, ICP-MS, NMR	Cytotoxicity, sensitization, implantation, genotoxicity assays
Output	Chemical identity & concentration data	Biological safety determination
Timing in development	Early — material selection & pre-submission	Mid to late — after chemical data is available
Animal use	None (purely analytical)	Possible, though increasingly minimized
Can one replace the other?	No — they are complementary	No — they are complementary

How Chemical Data Informs Biological Decisions

Chemical characterization data directly shapes which biocompatibility tests a device needs. If a thorough extractables study identifies no substances above toxicological concern thresholds, a manufacturer can document a scientific justification to waive certain biological tests. This approach saves time, reduces cost, and avoids unnecessary animal studies.

By contrast, if chemical characterization identifies substances of high concern — such as residual monomers, processing aids, or heavy metals — targeted biological testing becomes essential. For example, a device leaching a known sensitizer would trigger sensitization testing under ISO 10993-10 regardless of other data. Additionally, unexpected chemical findings can prompt further investigation using Chemical Purity & Contaminant Screening to fully characterize impurities before the toxicological risk assessment proceeds.

Experienced analytical teams and toxicologists need to collaborate closely throughout this process. Materials Metric’s Chemical & Analytical Testing services are specifically designed to generate the high-quality, regulatory-grade data that toxicologists and biological evaluators need to draw defensible conclusions. Explore additional research perspectives through resources such as PubMed Central – Trace Metals Review and peer-reviewed literature indexed in ScienceDirect – Analytical Methods.

Advanced Analytical Techniques Supporting Chemical Characterization vs Biocompatibility Decisions

Advanced analytical methods provide the backbone of rigorous chemical characterization programs. Selecting the right technique ensures that chemical findings are accurate, defensible, and directly useful for biocompatibility risk assessments. Furthermore, method selection must align with the specific chemical classes expected, the detection limits required, and the regulatory framework in scope.

ICP-MS and ICP-OES for Elemental Analysis

Inductively coupled plasma mass spectrometry (ICP-MS) delivers exceptional sensitivity for toxic metal detection. It quantifies elements at parts-per-trillion levels — making it the preferred method for device extracts where elemental impurities may be present at trace concentrations. Consequently, ICP-MS directly supports compliance with USP Elemental Impurities requirements and ISO 10993-18 elemental analysis protocols.

Inductively coupled plasma optical emission spectrometry (ICP-OES) offers a complementary approach. It handles higher concentration ranges and provides simultaneous multi-element detection across dozens of elements. For instance, screening a stainless steel implant for nickel, chromium, and cobalt leaching is a typical ICP-OES application in device biocompatibility programs.

Atomic Absorption Spectrometry in Device Testing

Atomic absorption spectrometry (AAS) targets specific elements with excellent precision. Unlike ICP techniques, AAS analyzes one element at a time — making it most efficient when a small, defined set of metals needs confirmation. Moreover, graphite furnace AAS (GF-AAS) achieves detection limits approaching those of ICP-MS for elements such as lead, cadmium, and arsenic.

Together, ICP-MS, ICP-OES, and AAS form a powerful elemental characterization toolkit. Regulatory-grade programs often use these methods in combination, cross-validating results to ensure data integrity. Materials Metric’s Chemical & Elemental Characterization team routinely selects and validates the most appropriate elemental technique for each specific device and material type.

Thermal and Structural Techniques Supporting Biocompatibility Decisions

Thermal analysis methods round out the characterization toolkit for polymeric and composite device materials. DSC Testing identifies phase transitions, crystallinity, and thermal stability — properties that directly influence how a polymer leaches chemicals under physiological conditions. Specifically, a material with a low glass transition temperature may release plasticizers or additives more readily at body temperature.

Structural and diffraction methods also contribute important information. XRD Analysis identifies crystalline phases in metallic alloys, ceramics, and coatings. Understanding phase composition helps predict corrosion behavior and long-term chemical stability — factors that directly influence leachable profiles and, ultimately, biocompatibility risk. Additionally, well-validated methods ensure that these data points hold up under regulatory scrutiny, which is why robust Method Development & Validation is essential for every characterization program.

Industry Applications: Where Chemical Characterization vs Biocompatibility Decisions Matter Most

The interplay between chemical characterization and biocompatibility extends well beyond medical devices. Numerous industries rely on the same foundational principles to protect human health, ensure product safety, and meet regulatory requirements. Understanding industry-specific applications helps teams identify the most relevant analytical strategy for their context.

Medical Devices and Pharmaceutical Packaging

Medical devices represent the most heavily regulated application of chemical characterization vs biocompatibility evaluation. Every implantable, blood-contacting, or mucosal-contact device must undergo biological evaluation under ISO 10993-1. Consequently, extractables and leachables studies are routine requirements for device manufacturers submitting 510(k), De Novo, or PMA applications to the FDA.

Pharmaceutical packaging presents closely related challenges. Primary packaging — vials, syringes, blister packs, and closures — contacts drug products directly and can leach chemicals into formulations. Therefore, extractables characterization of packaging materials is critical both for drug safety and for regulatory submissions under ICH Q3C (residual solvents) and ICH Q3D (elemental impurities). Our Wet Chemistry & Classical Analytical Methods services support these applications with well-established, regulatory-accepted techniques.

Aerospace and High-Performance Materials

Aerospace applications demand chemical characterization for different reasons. Material composition must be precisely controlled to ensure structural integrity, corrosion resistance, and compatibility with harsh operating environments. Furthermore, coatings, adhesives, and sealants used in aerospace assemblies must meet strict composition specifications.

Biocompatibility concerns arise in aerospace when materials contact crew members’ skin or breathing air — for example, cabin materials, oxygen system components, and life-support equipment. In such cases, outgassing characterization (identifying volatile organic compounds released by materials) functions as an aerospace equivalent of extractables testing. Similarly, toxicological assessment of identified compounds mirrors the biocompatibility risk assessment process used in medical device evaluation.

Environmental and Consumer Product Safety

Environmental laboratories apply chemical characterization principles to assess contaminant profiles in soil, water, and air samples. Regulatory frameworks such as EPA methods require sensitive, validated analytical techniques to quantify trace pollutants. Notably, many analytical methods used in device extractables studies — GC-MS, ICP-MS, HPLC — are direct adaptations of environmental monitoring techniques.

Consumer product safety programs also rely on chemical characterization to screen for restricted substances. For example, REACH compliance for chemicals in articles sold in the EU requires identification and quantification of substances of very high concern (SVHC). Consequently, Chemical Purity & Contaminant Screening services support both medical and non-medical clients navigating these requirements. Resources such as ScienceDirect provide peer-reviewed methodology references for both environmental and biomedical analytical applications.

Quality Assurance and Best Practices for Chemical Characterization vs Biocompatibility Programs

High-quality data is the foundation of every defensible biocompatibility package. Poor analytical practices — inadequate method validation, inappropriate extraction conditions, or incomplete reporting — are among the most common reasons regulators issue deficiency responses. Therefore, embedding quality assurance throughout the characterization process is not optional; it is essential.

Method Validation and Data Integrity

Every analytical method used in a regulatory submission must be appropriately validated. Validation confirms that a method is accurate, precise, specific, and sensitive enough to detect substances at concentrations that matter toxicologically. Specifically, method validation for extractables studies typically includes assessment of linearity, limits of detection (LOD), limits of quantitation (LOQ), recovery, and matrix effects.

Data integrity practices — including audit trails, calibration records, and instrument qualification — ensure that analytical results are traceable and reproducible. Furthermore, laboratories operating under ISO/IEC 17025 accreditation provide an additional layer of assurance that methods meet international quality standards. Materials Metric’s Method Development & Validation team develops fit-for-purpose analytical methods that satisfy both regulatory expectations and scientific rigor.

Extraction Condition Design and Worst-Case Scenarios

Choosing the right extraction conditions is a critical quality decision in any chemical characterization program. ISO 10993-18 requires that extraction conditions reflect realistic or exaggerated worst-case patient exposure. For instance, extraction solvents should mimic the chemical polarity of body fluids, and temperature or time conditions should accelerate release to ensure that all potentially leachable substances are detected.

Poorly chosen extraction conditions can lead to false negatives — substances present in a material go undetected because the extraction failed to release them. This outcome is particularly dangerous in biological evaluation because it creates an artificially clean chemical profile that does not represent true patient risk. Therefore, experienced analytical chemists must design extraction protocols thoughtfully, informed by material type, device contact conditions, and intended use.

Integrating Toxicological Risk Assessment

Chemical characterization data alone does not constitute a complete biological evaluation. A qualified toxicologist must review chemical findings, assess each identified substance against established toxicological thresholds, and generate a formal toxicological risk assessment (TRA). This TRA then feeds directly into the biological evaluation report (BER).

Toxicological thresholds — such as the threshold of toxicological concern (TTC) and substance-specific tolerable intake (TI) values — provide the scientific framework for deciding whether identified chemicals pose a risk. Moreover, if a substance lacks published toxicological data, a qualified toxicologist must derive a safety threshold from available in vitro or structural analog data. Materials Metric’s Scientific & Technical Consulting services provide expert toxicological and regulatory guidance throughout this process.

Best Practice	Why It Matters	Relevant Standard
Validate all analytical methods	Ensures data accuracy and regulatory acceptance	ISO/IEC 17025, ISO 10993-18
Use worst-case extraction conditions	Prevents false negatives in leachables profiles	ISO 10993-18
Apply multi-technique orthogonal analysis	Maximizes chemical coverage across compound classes	ISO 10993-18, FDA guidance
Conduct a qualified toxicological risk assessment	Links chemical data to biological safety decisions	ISO 10993-17
Document all decisions in a BEP and BER	Creates a traceable, auditable regulatory record	ISO 10993-1, FDA 2023 guidance
Engage expert consulting early	Prevents costly rework and submission delays	All applicable standards

Quick note: Regulatory agencies expect chemical characterization reports to include full analytical method details, instrument parameters, calibration data, and raw spectra or chromatograms. Submitting summary tables without supporting raw data is a frequent source of FDA information requests. Always retain complete analytical documentation in your technical file.

Frequently Asked Questions About Chemical Characterization vs Biocompatibility

Is chemical characterization required before biocompatibility testing?

Yes — regulatory guidance strongly recommends completing chemical characterization before finalizing a biocompatibility testing plan. Specifically, ISO 10993-18 and ISO 10993-1 together establish that chemical data should inform which biological endpoints require testing. Moreover, FDA reviewers expect a documented rationale linking chemical findings to biological test selection decisions.

Can chemical characterization data replace biocompatibility testing entirely?

In some cases, yes — but only partially, and only with rigorous scientific justification. If chemical characterization shows that all identified substances fall below established toxicological thresholds, certain biological tests may be waived. However, most regulatory submissions still require at least cytotoxicity data as a baseline biological screen. Additionally, contact type and duration heavily influence which tests cannot be waived regardless of chemical data.

What is a threshold of toxicological concern (TTC), and why does it matter?

A threshold of toxicological concern (TTC) is a conservative exposure level below which a chemical is considered unlikely to pose a significant risk to human health — even without substance-specific toxicological data. In practice, if a leachable substance is quantified below its applicable TTC, a toxicologist can document a risk-based justification to waive targeted biological testing for that substance. Consequently, TTC application is a powerful tool for streamlining biocompatibility programs without compromising patient safety.

How do extractables differ from leachables in a chemical characterization context?

Extractables are chemicals released from a material under exaggerated laboratory conditions — typically aggressive solvents, elevated temperatures, and extended contact times. Leachables, by contrast, are chemicals that actually migrate under real-world use conditions — normal solvents, body temperature, and actual contact durations. Therefore, extractables studies provide a comprehensive worst-case chemical inventory, while leachables studies confirm which substances a patient realistically encounters. Both data sets are necessary for a complete risk assessment.

Which ISO 10993 parts govern chemical characterization vs biocompatibility testing?

Chemical characterization falls primarily under ISO 10993-18 (chemical characterization of materials) and ISO 10993-17 (toxicological risk assessment). Biocompatibility testing operates under ISO 10993-1 as the overarching framework, with specific biological endpoints addressed by parts such as ISO 10993-5 (cytotoxicity), ISO 10993-10 (sensitization), ISO 10993-11 (systemic toxicity), and ISO 10993-23 (irritation). Furthermore, ISO 10993-12 covers sample preparation and reference materials applicable to both chemical and biological test programs.

When should a manufacturer engage a testing laboratory for chemical characterization and biocompatibility support?

Ideally, manufacturers engage an experienced laboratory at the earliest stages of device development — during material selection and design finalization. Early engagement allows the analytical team to design an efficient, fit-for-purpose chemical characterization program. Furthermore, early involvement of a Scientific & Technical Consulting partner helps avoid downstream surprises that could delay regulatory submission or trigger costly design changes. Materials Metric’s Chemical & Analytical Testing team is available to advise on program design from the earliest project stages.

Conclusion

Understanding the distinction between chemical characterization vs biocompatibility is fundamental for any team developing, manufacturing, or evaluating medical devices or patient-contacting materials. Chemical characterization identifies what is in a material; biocompatibility assessment determines whether those findings pose a biological risk. Together, these two disciplines form a complete, regulatory-grade safety evaluation — and neither can substitute for the other.

Moreover, the quality of chemical characterization data directly determines the strength of every downstream biological safety decision. Poorly designed extractables studies, unvalidated methods, or incomplete reporting create vulnerabilities that regulators will identify. By contrast, a well-executed chemical characterization program — built on orthogonal analytical techniques, validated methods, and expert toxicological interpretation — gives manufacturers the confidence to make defensible biocompatibility decisions quickly.

As regulatory expectations continue to evolve under updated FDA guidance and ISO 10993 standards, staying ahead requires both scientific depth and regulatory fluency. Ultimately, teams that invest in thorough chemical characterization early in development experience fewer deficiency letters, shorter review timelines, and stronger submissions overall.

Materials Metric provides comprehensive support across the full chemical characterization and biocompatibility evaluation workflow — from Chemical & Analytical Testing and Chemical & Elemental Characterization to Biocompatibility & Toxicity Testing and expert Scientific & Technical Consulting. Our team brings deep analytical expertise, regulatory knowledge, and a commitment to data quality that submission packages demand.

Ready to build a stronger, more efficient biological evaluation program? Contact Materials Metric today to discuss your chemical characterization or biocompatibility testing needs with our expert team.